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HIV-infected individuals are at increased risk of right and left heart dysfunction. N-terminal-
pro-brain natriuretic peptide (NT-proBNP), a marker of cardiac ventricular strain and systolic
dysfunction, may be associated with all-cause mortality in HIV-infected women. The aim of
this study was to determine if elevated levels of NT-proBNP is associated with increased




Wemeasured NT-proBNP in 936 HIV-infected and 387 age-matched HIV-uninfected
women early (10/11/94 to 7/17/97) and 1082 HIV-infected and 448 HIV-uninfected women
late (4/1/08 to 10/7/08) in the highly active antiretroviral therapy (HAART) periods in the
Women’s Interagency HIV Study. An NT-proBNP >75th percentile was more likely in HIV-
infected persons, but only statistically significant in the late period (27% vs. 21%, unadjust-
ed p = 0.03). In HIV-infected participants, NT-proBNP>75th percentile was independently
associated with worse 5-year survival in the early HAART period (HR 1.8, 95% CI 1.3–2.4,
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p<0.001) and remained a predictor of mortality in the late HAART period (HR 2.8, 95% CI
1.4–5.5, p = 0.002) independent of other established risk covariates (age, race/ethnicity,
body mass index, smoking, hepatitis C serostatus, hypertension, renal function, and hemo-
globin). NT-proBNP level was not associated with mortality in HIV-uninfected women.
Conclusion
NT-proBNP is a novel independent marker of mortality in HIV-infected women both when
HAART was first introduced and currently. As NT-proBNP is often associated with both pul-
monary hypertension and left ventricular dysfunction, these findings suggest that these con-
ditions may contribute significantly to adverse outcomes in this population, requiring further
definition of causes and treatments of elevated NT-proBNP in HIV-infected women.
Introduction
While highly active antiretroviral therapy (HAART) has reduced mortality related to infectious
complications in people with HIV, they are more likely than HIV-uninfected persons to have
subclinical cardiovascular disease[1] or be diagnosed with myocardial infarction, congestive
heart failure, cardiomyopathy, pulmonary hypertension, and chronic obstructive pulmonary
disease (COPD).[2–6] Additionally, HAART may play a role in the development of cardiovas-
cular disease.[7,8] A prior study showed increased cardiac risk factors and rates of acute myo-
cardial infarction in HIV-infected women compared to HIV-uninfected women,[2] suggesting
that a better understanding of cardiovascular disease prevalence, risk factors, and outcomes in
women with chronic HIV infection is needed.
Several studies have linked markers of inflammation and altered coagulation with increased
cardiovascular disease and mortality in HIV.[9–11] C-reactive protein (CRP), interleukin (IL)-
6, and D-dimer correlate with traditional markers of HIV infection severity, CD4 count and
plasma HIV RNA levels, but are also independently associated with mortality in HIV-infected
persons. Similar to HIV-uninfected populations, these markers and other inflammatory mark-
ers also correlate with comorbid cardiovascular and pulmonary disease.[12,13]
N-terminal-pro-brain natriuretic peptide (NT-proBNP) is biomarker of cardiac dysfunction
that is associated with poor prognosis in several diseases. NT-proBNP is a marker of both left
and right heart disease and is released by cardiac myocytes in response to increased wall stress.
[14–16] Elevated NT-proBNP levels have been associated with worse outcomes, including
mortality, in populations with congestive heart failure (CHF), pulmonary hypertension, sickle
cell disease, and COPD.[17–22] Prior work has shown that brain natriuretic peptide is elevated
in HIV-infected persons with right and left heart dysfunction.[23–26] Elevated NT-proBNP
was also associated with increased risk for cardiovascular events in HIV-infected persons[27].
Additionally, HIV-infected women have been shown to have higher levels of NT-proBNP com-
pared to HIV-uninfected women, but because this has been attributed to an increased preva-
lence of non-HIV-related factors such as anemia, kidney disease, and hepatitis C infection,
NT-proBNP may be a global marker of comorbidity in HIV infection.[28] NT-proBNP has not
been evaluated as a marker of mortality in HIV populations. A better understanding of the
pathogenesis, risk factors, and outcomes related to cardiac and pulmonary disease in HIV-in-
fected persons is important for both clinical care and research investigations.
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We tested the hypothesis that elevated NT-proBNP was associated with mortality in HIV-
infected women in the early (1994–1997) and recent (2008) HAART periods using data from
the Women’s Interagency HIV Study (WIHS).
Methods
Participants
TheWIHS cohort has been described previously and is a well-characterized, prospective cohort
started in 1994 that is comprised of 3,067 HIV-infected women and 1,070 HIV-uninfected
women with high risk for exposure to HIV.[29] We randomly selected half of the HIV-infected
participants with plasma samples available from a visit at an early HAART period (10/11/94 to
7/17/97) and half of the HIV-infected participants with a plasma sample available during a late
HAART period (4/1/08 to 10/7/08). HIV-uninfected participants with plasma samples avail-
able were proportionally matched 1:2 by age at each time period. The institutional review
boards of participating institutions (University of Pittsburgh; Women’s Interagency HIV Study
Data Management and Analysis Center; Johns Hopkins University; University of California,
San Francisco; State University of New York Downstate Medical Center) approved the study
protocol, and written informed consent was obtained from all participants.
Data collection
At six-month visits, age, race/ethnicity, body mass index (BMI), cigarette smoking status, alco-
hol consumption, use of intravenous drugs in the past 6 months, use of cocaine in the past 6
months, and use of HAART were collected by participant interview. Alcohol consumption was
categorized as none, light drinking (<3 drinks/week), moderate drinking (3–13 drinks/week),
or heavy drinking (14 drinks/week). HAART was defined previously,[30] and antiretroviral
medication use was categorized as none, single or combination (not HAART), or current
HAART use. HIV status was determined by HIV serological testing at each visit in previously
seronegative participants, and participants who were HIV positive at baseline visit were as-
sumed to have duration of HIV infection from time of WIHS enrollment to the date corre-
sponding to NT-proBNP measurement. CD4 count and plasma HIV RNA level were
measured at each visit. Deaths were ascertained by National Death Index-Plus match and
causes of death were confirmed primarily by AIDS registry data (25%), death certificate review
(13%), or both (52%), and defined as previously described.[31]
NT-proBNP was measured in stored plasma using Roche Pro-BNP assay kit with the
Elecsys 2010 according to the manufacturer’s instructions (Roche Diagnostics, Indianapolis,
IN). When originally collected, blood was drawn into Cell Preparation Tubes (BD Diagnostics,
New Jersey, United States) and processed within 6 hours by centrifuging at 1500g at room tem-
perature. Plasma was aliquoted and stored at -80° C in a central repository until assayed in the
fall of 2011, whether they were collected in the early (10/11/94 to 7/17/97) or late (4/1/08 to 10/
7/08) HAART periods.[32,33] Because of the effect of decreased renal function on NT-proBNP
levels, participants with an estimated creatinine clearance below 60 mL/min were excluded
from analyses (167 in the early HAART period and 135 in the late HAART period).[34,35]
Statistical analysis
Covariates were extracted from the visit data corresponding to the time of the plasma sample
that was used to measure NT-proBNP was drawn, which we considered the index visit. Data
missing from the index visit were imputed from the last observation carried forward if the data
were available from a visit within one year prior for the variables creatinine and hemoglobin. If
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observations had missing data despite these imputations, the observation was not included in
the analysis which excluded 204 participants in the early HAART period and 122 from the late
HAART period.
Personal characteristics, clinical data, and NT-proBNP levels were described and compared
between HIV-infected and HIV-uninfected groups during the early HAART period and late
HAART period using t-test, Kruskal-Wallis test, and chi-squared test. NT-proBNP level was
dichotomized using the 75th percentile of the cohort to define an elevated level because a nor-
mal range or clinical cut-off is not defined for this population. For modeling purposes, continu-
ous covariates were categorized into quartiles.
To determine factors associated with elevated NT-proBNP level in both the early and late
HAART periods, multivariable logistic regression was used. In both HAART periods, multivar-
iable logistic regression models were developed for HIV-infected only, HIV-uninfected only,
and all (HIV-uninfected and HIV-infected) groups. The following covariates were considered
in the analyses: age, race/ethnicity, body mass index, smoking status, alcohol use, illicit drug
use, hepatitis C serostatus, hypertension, renal function, hemoglobin, history of AIDS, antire-
troviral use, CD4 count, and viral load. In models of HIV-infected women only, the HIV-relat-
ed variables CD4 count, HIV RNA levels, ART use, and history of AIDS were considered in
model creation. Predictors were included in the final multivariable logistic regression models if
they met a cutoff p-value of 0.25 in a univariate logistic regression and remained statistically
significant at p-value< 0.05 in a multivariable logistic regression that included other signifi-
cant predictors. A predictor whose exclusion from or inclusion in the final multi-predictor
model markedly affected the estimated coefficients of the other predictors was kept in the
model regardless of the p-value associated with it.
We used Cox proportional hazards regression to assess association between elevated NT-
proBNP level (greater than the 75th percentile) and mortality. Baseline hazards models were
substantially different for HIV-infected and HIV-uninfected groups and for the early and late
HAART periods, and survival models were developed separately for HIV-infected and HIV-
uninfected patient groups in both the early and late HAART periods. The same predictor selec-
tion strategy as in the development of the logistic regression models was used to arrive at the
final Cox regression models. Time origin was the date of the collection of the plasma sample on
which NT-proBNP was measured. Subjects were observed until death, loss to follow-up or lat-
est date of data collection, 7/19/2012. Subjects lost to follow-up were censored at their last visit
time. Subjects known to be alive as of the last date of data collection (7/19/2012) were censored
at their last visit time.
Due to significant departure from the proportional hazards assumption for the Cox regres-
sion model fitted for the entire follow-up period in the HIV-infected group from the early
HAART, a Cox regression model was fitted separately for the first 5 years of follow-up period
only.[36] Adjusted survival curves under the Cox proportional hazards model were also calcu-
lated for each comparison using the average value for covariates in the models. Two sided-val-
ues<0.05 were considered significant. To determine the level of NT-proBNP above which is
most associated with a decreased survival (greater risk of mortality), we determined a cut-point
in the NT-proBNP variable that gives the best separation of the two groups in survival as mea-
sured by the log rank statistics using the maxstat package in R (Torsten Hothorn [2014]. max-
stat: Maximally Selected Rank Statistics. R package version 0.7–20. http://CRAN.R-project.org/
package=maxstat).
To determine if an elevated baseline NT-proBNP was associated with cardiac causes of
death, we compared the numbers of death identified as “heart” (myocardial infarction, conges-
tive heart failure, surgery on heart vessels, or other heart disease) or “pulmonary hypertension”
vs. all other causes of death in those with elevated NT-proBNP vs. non-elevated NT-proBNP
BNP and Survival in HIV
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stratified by HIV status and HAART period using the chi-squared test. SAS Version 9.2 (SAS,
Inc., Cary, NC) was used for the analysis unless otherwise stated.
Results
Participant characteristics
NT-proBNP was measured in 936 HIV-infected and 387 HIV-uninfected individuals in the
early HAART period and 1082 HIV-infected and 448 HIV-uninfected individuals in the late
HAART periods. HIV-infected participants differed from HIV-uninfected participants in both
the early and late HAART periods (Tables 1 and 2).
Table 1. Early HAART cohort.
HIV-uninfected HIV-infected Overall P-value
(N = 387) (N = 936) (N = 1323)
Mean (SD) Mean (SD) Mean (SD)
n (%) n (%) n (%)
Age (years) 34.8 (8.3) 36.8 (7.7) 36.2 (7.9) <0.001
African American 207 (54%) 541 (58%) 748 (57%) 0.15
Hispanic 10 (3%) 39 (4%) 49 (4%) 0.17
Body mass index (kg/m2) 28.5 (7.3) 27.0 (6.4) 27.4 (6.7) <0.001
Smoking Status 0.28
Never smoker 96 (25%) 260 (28%) 356 (27%)
Current smoker 225 (58%) 499 (53%) 724 (55%)
Former smoker 66 (17%) 177 (19%) 243 (18%)
Alcohol use <0.001
None 184 (48%) 549 (59%) 733 (55%)
Light 100 (26%) 219 (23%) 319 (24%)
Moderate 70 (18%) 97 (10%) 167 (13%)
Heavy 33 (9%) 71 (8%) 104 (8%)
Illicit drug use, ever 307 (79%) 707 (76%) 1014 (77%) 0.14
Intravenous drug use, ever 57 (15%) 110 (12%) 167 (13%) 0.14
Cocaine use, ever 135 (35%) 270 (29%) 502 (38%) 0.03
Hepatitis C positive 111 (29%) 391 (42%) 502 (38%) <0.001
Hypertension 91 (24%) 203 (22%) 294 (22%) 0.47
Creatinine (mg/dL) 0.87 (.16) 0.88 (.17) 0.88 (.17) 0.53
Hemoglobin (gm/dL) 13.1 (1.2) 12.3 (1.5) 12.5 (1.5) <0.001
History of AIDS 607 (65%) n/a
Antiretroviral medication use n/a
None 414 (44%)
Prior HAART 483 (52%)
Current HAART 39 (4%)
HAART duration 0.00 (.05) n/a
CD4 counts: Current, at baseline pulmonary 1086 (388) 356 (281) 565 (457) <0.001
CD4 counts: Mean over follow-up period 1256 (412) 439 (321) 673 (508) <0.001
CD4 counts: Nadir over follow-up period 910 (321) 289 (235) 467 (384) <0.001
Plasma HIV RNA level (copies/mL) 18x103 (1x105) n/a
HIV RNA detectable 842 (90%) n/a
NT-proBNP (above 3rd Quartile) 86 (22%) 245 (26%) 331 (25%) 0.13
doi:10.1371/journal.pone.0123389.t001
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Predictors of elevated NT-proBNP
In the entire cohort, the 75th percentile of NT-proBNP level in the early HAART period was
58.7ng/L. An elevated (>75th percentile) NT-proBNP level was associated with advanced age,
African American race, lower body mass index, smoking, Hepatitis C seropositive status, lower
hemoglobin level, and presence of hypertension (Table 3—early HAART period). In the entire
cohort during the late HAART period, the 75th percentile of NT-proBNP level was 60.6ng/L,
and an elevated NT-proBNP level was associated with same findings as the early period except
African American race and hypertension (Table 3—late HAART period). The presence of ele-
vated NT-proBNP levels was higher among HIV-infected women than in uninfected women in
Table 2. Late HAART cohort.
HIV-uninfected HIV-infected Overall P-value
(N = 448) (N = 1082) (N = 1530)
Mean (SD) Mean (SD) Mean (SD)
n (%) n (%) n (%)
Age (years) 40.9 (9.7) 44.5 (8.2) 43.4 (8.8) <0.001
African American 287 (64%) 614 (57%) 901 (59%) 0.008
Hispanic 61 (14%) 156 (14%) 217 (14%) 0.68
Body mass index (kg/m2) 31.5 (8.7) 29.6 (7.5) 30.2 (7.9) <0.001
Smoking Status <0.001
Never smoker 112 (25%) 360 (33%) 472 (31%)
Current smoker 220 (49%) 390 (36%) 610 (40%)
Former smoker 116 (26%) 332 (31%) 448 (29%)
Alcohol use <0.001
None 193 (43%) 682 (63%) 875 (57%)
Light 156 (35%) 276 (26%) 432 (28%)
Moderate 74 (17%) 92 (9%) 166 (11%)
Heavy 25 (6%) 32 (3%) 57 (4%)
Illicit drug use, ever 295 (66%) 516 (48%) 811 (53%) <0.001
Intravenous drug use, ever 40 (9%) 71 (7%) 111 (7%) 0.10
Cocaine use, ever 171 (38%) 293 (27%) 464 (30%) <0.001
Hepatitis C positive 73 (16%) 265 (25%) 338 (22%) <0.001
Hypertension 135 (30%) 341 (32%) 476 (31%) 0.59
Creatinine (mg/dL) 0.80 (.15) 0.79 (.16) 0.79 (.16) 0.29
Hemoglobin (gm/dL) 12.6 (1.3) 12.4 (1.4) 12.5 (1.4) 0.02
History of AIDS 478 (44.2%) n/a
Antiretroviral medication use n/a
None 221 (20%)
Prior HAART 12 (1%)
Current HAART 849 (79%)
HAART duration 8.04 (3.8) n/a
CD4 counts: Current, at baseline pulmonary 1081 (394) 520 (290) 684 (413) <0.001
CD4 counts: Mean over follow-up period 1443 (500) 821 (387) 1003 (509) <0.001
CD4 counts: Nadir over follow-up period 754 (274) 224 (165) 379 (315) <0.001
Plasma HIV RNA level (copies/mL)* 80.0 (1x103) n/a
HIV RNA detectable 426 (39%) n/a
NT-proBNP (above 3rd Quartile) 95 (21%) 288 (27%) 383 (25%) 0.03
doi:10.1371/journal.pone.0123389.t002
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both the early and late HAART periods, but this difference was only statistically significant in
the later period (27% of HIV-infected participants with elevated NT-proBNP vs. 21% of HIV-
uninfected, unadjusted p = 0.03). HIV status did not remain associated with elevated NT-
proBNP level in the late HAART period after adjustment in the multivariable model. In HIV-
infected participants, during the early and late HAART periods, the 75th percentile NT-
proBNP levels were 60.8ng/L and 63.3ng/L, respectively. Factors associated with elevated NT-
proBNP (>75th percentile) in HIV-infected participants were similar in the early and late
HAART periods except that African-American race was significantly associated with elevated
NT-proBNP level in the early period, and in the late period, light drinking was associated with
lower and heavy drinking associated with higher NT-proBNP levels (Table 4). No HIV-related
factors were found to be associated with NT-proBNP level, and cocaine use was not associated
with elevated NT-proBNP.
Association of NT-proBNP level with mortality
We analyzed mortality in relation to NT-proBNP levels in HIV-infected participants in the
early (n = 936; 403 mortality events) and late (n = 1082; 55 mortality events) HAART periods
Table 3. Factors associated with an elevated BNP (>75th percentile) in the entire cohort in early and
late HAART periods.
Early HAART period OR 95% CI p-value
HIV infection 0.84 03.62–1.15 0.27
Age Q2 (ref = Q1) 2.08 1.39–3.16 <0.001
Age Q3 2.27 1.51–3.45 <0.001
Age Q4 3.06 2.04–4.65 <0.001
African American (ref = white, non-Hispanic) 0.47 0.33–0.66 <0.001
Hispanic (ref = white, non-Hispanic) 0.61 0.41–0.91 0.01
Hemoglobin Q2 (ref = Q1) 0.44 0.31–0.63 <0.001
Hemoglobin Q3 0.32 0.21–0.47 <0.001
Hemoglobin Q4 0.25 0.17–0.36 <0.001
Hypertension 1.61 1.17–2.19 0.003
Late HAART period OR 95% CI p-value
HIV infection 1.13 0.85–1.51 0.41
Age Q2 (ref = Q1) 1.72 1.17–2.55 0.006
Age Q3 1.89 1.28–2.82 0.002
Age Q4 2.39 1.59–3.63 <0.001
Hypertension 1.72 1.30–2.28 <0.001
BMI Q2 (ref = Q1) 0.66 0.47–0.93 0.02
BMI Q3 0.49 0.34–0.69 <0.001
BMI Q4 0.69 0.49–0.97 0.03
Hepatitis C antibody positive 1.52 1.13–2.05 0.006
Hemoglobin Q2 (ref = Q1) 0.72 0.51–1.01 0.06
Hemoglobin Q3 0.49 0.35–0.70 <0.001
Hemoglobin Q4 0.43 0.30–0.62 <0.001
African American (ref = white, non-Hispanic) 0.66 0.48–0.91 0.01
Hispanic (ref = white, non-Hispanic) 0.82 0.56–1.19 0.3
Smoking—current (ref = never smoking) 1.37 1.00–1.89 0.050
Smoking—former 0.86 0.61–1.20 0.36
Q = quartile; BMI = body mass index.
doi:10.1371/journal.pone.0123389.t003
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and in the HIV-uninfected participants in the early HAART period (n = 387; 48 mortality
events). There were too few deaths in the HIV-uninfected group to assess an association with
NT-proBNP level in the late HAART period (n = 4). In HIV-infected participants, NT-
proBNP>75th percentile was independently associated with greater 5-year mortality in the
early (HR 1.78, 95% CI 1.31–2.42, p<0.001) and in the late (HR 2.81, 95% CI 1.61–4.91,
p = 0.002) periods (Fig. 1). These associations were independent of other factors associated
with mortality including HIV-related variables such as HAART use, CD4 T-lymphocyte cell
count, and HIV RNA levels. In HIV-uninfected women in the early period, elevated NT-
proBNP level was not associated with mortality. In the early period (from 10/11/94 to 7/17/97)
the optimal cut-point above which was associated with worse survival was 70.2 ng/L which was
the 80th percentile. In the late period (from 4/1/08 to 10/7/08) the optimal cut-point was 114.8
ng/L which corresponded to the 90th percentile.
Mortality outcomes
There were very few deaths clinically attributed to cardiac disease in the early and late HAART
periods in either the HIV-infected or HIV-uninfected participants. In the HIV-infected partici-
pants from the early HAART period, 3% in the low NT-proBNP group and 5% in the elevated
NT-proBNP group had causes of death related to defined cardiac disease (p = 0.43). In the
HIV-uninfected participants from the early HAART group, 3% in the low NT-proBNP and
12% from the high NT-proBNP group had cardiac related deaths (p = 0.28). In the HIV-in-
fected participants from the late HAART period, there have been zero deaths attributed to car-
diac causes in the low NT-proBNP group, but 9% in the elevated NT-proBNP group had
causes of death related to cardiac disease (p = 0.24).
Table 4. Factors associated with an elevated NT-proBNP (>75th percentile) in HIV-infected partici-
pants in the early and late HAART periods.
Early HAART period OR 95% CI p-value
Hypertension 1.89 1.31–2.74 <0.001
Hepatitis C antibody positive 2.14 1.56–2.96 <0.001
Hemoglobin Q2 (ref = Q1) 0.40 0.26–0.60 <0.001
Hemoglobin Q3 0.26 0.17–0.41 <0.001
Hemoglobin Q4 0.16 0.10–0.26 <0.001
African American (ref = white non-Hispanic) 0.60 0.39–0.89 0.02
Hispanic (ref = white non-Hispanic) 0.78 0.46–1.21 0.31
Late HAART period OR 95% CI p-value
Hypertension 1.77 1.31–2.38 <0.001
Drinking, light (ref = abstinent) 0.66 0.45–0.93 0.03
Drinking, moderate 1.30 0.77–2.10 0.31
Drinking, heavy 2.81 1.25–5.73 0.008
Hepatitis C antibody positive 2.25 1.58–2.99 <0.001
Hemoglobin Q2 (ref = Q1) 0.87 0.58–1.28 0.48
Hemoglobin Q3 0.52 0.35–0.79 0.002
Hemoglobin Q4 0.49 0.32–0.73 <0.001
Q = quartile.
doi:10.1371/journal.pone.0123389.t004
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Discussion
This analysis is the first to identify NT-proBNP, a marker of cardiac stress, as independently
associated with mortality in HIV-infected women. Elevated NT-proBNP was not related to
HIV severity such as CD4 count or plasma HIV RNA level, and the association of NT-proBNP
with mortality was independent of CD4 count and plasma HIV RNA level. Additionally, the ef-
fect size of elevated NT-proBNP on mortality in the HIV-infected group was greater in the late
period where HAART use was more common. Because NT-proBNP is a sensitive marker for
cardiac wall stress (which may be left- or right-sided), these findings could reflect cardiac or
pulmonary vascular disease as a significant contributor to HIV-related comorbidity and mor-
tality in the HIV population, but recent studies illustrating that the production/secretion of na-
triuretic peptide is also strongly influenced by other inflammatory, physiologic, and toxic
processes may also help explain our findings in the HIV population.
As in the general population, elevated NT-proBNP levels reflect cardiac and pulmonary vas-
cular disease in HIV-infected individuals. Several studies in HIV-infected populations have
shown elevated BNP associated with increased rates of heart failure, cardiomyopathy, coronary
Fig 1. a) Cox adjusted survival curves for HIV-infected participants with NT-proBNP75th percentile (solid) and HIV-infected with NT-
proBNP>75th percentile (dash) during the early HAART period. b) Cox adjusted survival curves for HIV-uninfected participants with NT-proBNP75th
percentile (solid) and HIV-uninfected participants with NT-proBNP>75th percentile (dash) during the early HAART period. c) Cox adjusted survival curves for
HIV-infected participants with NT-proBNP75th percentile (solid) and HIV-infected participants with NT-proBNP>75th percentile (dash) during the late
HAART period. aHR = adjusted hazard ratio; 95% CI = 95% confidence interval for the adjusted hazard ratio.
doi:10.1371/journal.pone.0123389.g001
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artery disease, pulmonary hypertension, and left and right heart abnormalities measured by
echocardiogram and magnetic resonance imaging.[24,25,27,37] A prior publication in a
smaller subgroup from the WIHS cohort found HIV-infected participants had higher NT-
proBNP levels, and NT-proBNP was associated with typical risk factors for cardiac and pulmo-
nary disease such as age, race, body mass index, smoking, illicit drug use, hepatitis C infection,
hemoglobin, and hypertension.[28] NT-proBNP may also be produced and secreted in re-
sponse to mechanisms related to other common phenomenon in the HIV population such as
increased inflammatory cytokines important in the pathogenesis of cardiomyopathy—interleu-
kin-1, interleukin-6, and tumor necrosis factor-α,[38,39] exposure to toxins such as cocaine
which has cardio-toxic effects,[40,41] and lipotoxicity which can lead to metabolic and cardiac
disease.[42,43] Adjusting for other variables, no HIV-related variables were associated with ele-
vated NT-proBNP, and HIV infection was not an independent predictor for elevated NT-
proBNP after adjusting for anemia, hepatitis C infection, and impaired kidney function, which
were more common in the HIV-infected participants. Our findings of associations of NT-
proBNP in HIV-infected women were similar to prior work, but this is the first study, to our
knowledge, to assess the association between NT-proBNP and mortality in HIV.
We demonstrated that an elevated NT-proBNP was associated with increased all-cause
mortality in HIV-infected participants, but was not significantly associated with mortality in
the HIV-uninfected group from the same cohort and similar HIV risk factors. Elevated BNP
levels are associated with increased mortality in patients with cardiac and pulmonary diseases,
[17–20,22] and NT-proBNP was also a marker of mortality and cardiovascular events in a
community sample, the Framingham Offspring Study.[44] The participants in our study were
much younger than the Framingham Offspring study (35 years old in the early HAART period
and 43 in the late HAART period compared to 60 years old in Framingham) suggesting that
HIV-infected individuals may have an accelerated risk of NT-proBNP-related pathology. The
younger age may also explain why we did not see a significant association between elevated
NT-proBNP and mortality in the HIV-uninfected participants.
NT-proBNP was not associated with degree of immunosuppression and its relationship
with mortality was seen in both the early and late HAART periods. Baseline CD4 count and
plasma HIV RNA level were not associated with NT-proBNP in either the early HAART peri-
od, when few participants were on effective HAART or virally-suppressed, or in the late
HAART period, when most were on successful HAART. These findings contrast with prior
studies of biomarkers associated with mortality in HIV.[9,12] For example, biomarkers of in-
flammation and coagulation such as CRP, IL-6, and D-dimer were often associated with greater
viral levels or lower CD4 counts;[9,10,12,45] however, NT-proBNP, a protein derived from
cardiac myocytes, was not associated with these traditional HIV markers. Lack of association
with traditional HIV markers may indicate that a mechanism independent of severity of HIV
disease is involved in the association between elevated NT-proBNP levels and mortality.
The underlying cause of the relationship between mortality in HIV infection and elevated
NT-proBNP is unclear. Several studies in HIV have shown elevated BNP is associated with car-
diac dysfunction,[24,25,37] and because inflammation, cocaine use, and metabolic disease can
be other mechanisms leading to increased NT-proBNP and are common in HIV-infected per-
sons, NT-proBNP may be a surrogate risk marker of ongoing cardiac damage from chronic in-
flammation, illicit drug use, or metabolic disease in the HIV-population.[38–43] We assessed
the cause of death in relationship to elevated NT-proBNP level to see if the association was re-
lated to cardiac disease specifically, but very few causes of death were clinically attributed to
cardiac cause in the early and late HAART periods. This study and others have also found that
hepatitis C infection and anemia are independently associated with elevated NT-proBNP, and
renal disease is known to affect NT-proBNP levels.[34,46,47] We excluded persons with
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reduced renal function and used the calculated creatinine clearance in modeling to eliminate
potential confounding from significant renal disease that would alter NT-proBNP level and
mortality; however, there may be residual confounding from these factors that could explain
the association we find between NT-proBNP level and mortality. Further study in a prospective
manner may be necessary to determine exactly how NT-proBNP links HIV infection and mor-
tality. As NT-proBNP is significantly associated with mortality risk and is a readily available
and inexpensive test, it may be a useful marker to determine elevated risk of death in the HIV-
infected population. Further evaluation of NT-proBNP as a screening test for cardiopulmonary
disease in the HIV-infected population is warranted.[28]
Our study has several unique strengths as well as important limitations. We expand on
prior findings in the WIHS cohort that NT-proBNP is associated with co-morbidities and
show there is also a significant association with mortality. This study benefits from the strength
of a well-characterized and prospectively followed cohort of HIV-infected and high-risk HIV-
uninfected women with similar baseline characteristics. Also, we were able to assess the effect
treatment has on the relationship between NT-proBNP and mortality by including both an
early HAART period where viral suppression was not common and a later HAART period
with high prevalence of antiretroviral use and viral suppression. This cohort is unique in that it
is strictly women and comprised primarily of minorities with a history of engaging in high-risk
behavior, predominantly illicit drug use. It is unknown if the current findings would be applica-
ble to men (however, since men are at risk for earlier cardiovascular disease, it may be more ap-
plicable) or those without illicit drug use or intravenous drug use behaviors. We were also not
able to look at specific diseases that may contribute to the NT-proBNP such as pulmonary hy-
pertension, atherosclerosis, cardiomyopathy, etc. Another limitation is that NT-proBNP was
not measured at the time the plasma sample was obtained. Degradation of the NT-proBNP
peptide in storage is possible and could influence the absolute level of NT-proBNP. Storage in
-80° C should limit degradation, and our early period levels were expected to be lower due to
younger age of the cohort at that time, and NT-proBNP correlated with other biomarkers as
expected (hemoglobin, creatinine, etc). In addition, the relative relationships should be ex-
pected to be unaltered by the degradation.
In conclusion, we have found a novel biomarker for mortality in HIV-infected women that
is independent of CD4 counts or plasma HIV RNA levels. As NT-proBNP is a marker of car-
diovascular and pulmonary disease in the general population and this HIV cohort is relatively
younger than those in general population-based studies, our findings suggest that HIV-infected
women may be at increased risk for cardiopulmonary comorbidities that could lead to in-
creases in mortality. Elevated NT-proBNP in HIV-infected women may be a useful marker for
risk stratification and aid in the investigation of comorbid complications of HIV.
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